Advertisement

Topics

QIAGEN and Inovio Partner to Develop Companion Diagnostic for Novel Immunotherapy Targeting Precancerous Cervical Lesions

09:59 EDT 17 May 2019 | Speciality Pharma Journal

Hilden, Germany, Germantown, Maryland, and Plymouth Meeting, Pennsylvania, May 16, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Inovio Pharmaceuticals Inc. (NASDAQ: INO) today announced a collaboration to co-develop a companion diagnostic to guide clinical decision-making for the use of Inovio’s DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV). The …

Original Article: QIAGEN and Inovio Partner to Develop Companion Diagnostic for Novel Immunotherapy Targeting Precancerous Cervical Lesions

NEXT ARTICLE

More From BioPortfolio on "QIAGEN and Inovio Partner to Develop Companion Diagnostic for Novel Immunotherapy Targeting Precancerous Cervical Lesions"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...